CYTOMX THERAPEUTICS INC's ticker is CTMX and the CUSIP is 23284F105. A total of 121 filers reported holding CYTOMX THERAPEUTICS INC in Q4 2019. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2022 | $51,000 | -50.0% | 18,904 | -18.9% | 0.00% | – |
Q4 2021 | $102,000 | -9.7% | 23,322 | +4.9% | 0.00% | – |
Q3 2021 | $113,000 | -37.2% | 22,232 | -22.0% | 0.00% | -100.0% |
Q2 2021 | $180,000 | -8.2% | 28,508 | +12.2% | 0.00% | 0.0% |
Q1 2021 | $196,000 | +75.0% | 25,408 | +48.3% | 0.00% | – |
Q4 2020 | $112,000 | +30.2% | 17,138 | +32.0% | 0.00% | – |
Q3 2020 | $86,000 | -23.2% | 12,981 | -3.7% | 0.00% | -100.0% |
Q2 2020 | $112,000 | -15.2% | 13,475 | -15.4% | 0.00% | 0.0% |
Q4 2019 | $132,000 | +3.1% | 15,930 | -8.3% | 0.00% | 0.0% |
Q3 2019 | $128,000 | -36.3% | 17,365 | -3.2% | 0.00% | 0.0% |
Q2 2019 | $201,000 | -7.4% | 17,940 | -11.0% | 0.00% | 0.0% |
Q1 2019 | $217,000 | -27.9% | 20,163 | +1.1% | 0.00% | -50.0% |
Q4 2018 | $301,000 | -31.6% | 19,943 | -16.1% | 0.00% | -33.3% |
Q3 2018 | $440,000 | -10.2% | 23,783 | +10.9% | 0.00% | 0.0% |
Q2 2018 | $490,000 | -19.8% | 21,451 | -0.1% | 0.00% | -25.0% |
Q1 2018 | $611,000 | +15.7% | 21,472 | -14.1% | 0.00% | 0.0% |
Q4 2017 | $528,000 | – | 25,006 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
BVF INC/IL | 5,803,700 | $25,130,000 | 0.91% |
Altium Capital Management LP | 663,800 | $2,874,000 | 0.79% |
Rubric Capital Management LP | 2,406,449 | $10,420,000 | 0.49% |
RTW INVESTMENTS, LP | 6,029,700 | $26,109,000 | 0.38% |
Orbimed Advisors | 3,214,509 | $13,919,000 | 0.18% |
TANG CAPITAL MANAGEMENT LLC | 152,345 | $660,000 | 0.13% |
PLATINUM INVESTMENT MANAGEMENT LTD | 980,085 | $4,244,000 | 0.12% |
Point72 Asset Management, L.P. | 6,303,025 | $27,292,000 | 0.11% |
Sender Co & Partners, Inc. | 40,720 | $176,000 | 0.09% |
Manteio Capital LLC | 15,067 | $65,000 | 0.08% |